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Introduction: Chronic obstructive pulmonary disease (COPD) is a common cause of pre-
capillary pulmonary hypertension (PH). This complication may be overlooked in patients with
COPD, as symptoms frequently are attributed to ventilatory limitation. Predictors of PH may
identify patients with increased risk of morbidity and mortality.
Objective: The aims of this COPD study were to (i) evaluate the relationship between mean
pulmonary artery pressure (mPAP) and PaO2, (ii) identify significant predictors of mPAP and
PaO2 and (iii) use PaO2 as a marker of PH.
Methods: Altogether 95 COPD patients with mild to very severe airway obstruction and without
left ventricular (LV) dysfunction were included. Pulmonary function tests, right heart catheter-
izations and exercise tests with blood gases were performed.
Results: Multivariate regression analyses showed that only PaO2 was a significant predictor of
mPAP. FEV1 and mPAP were significant predictors of PaO2 both at rest and at peak exercise.
PaO2 at peak exercise was better to identify pulmonary hypertension than PaO2 at rest. By
combining PaO2 at rest and peak exercise, it was possible to predict PH with a detection rate
of 76% and a false-positive rate of 24%.
Conclusion: In an outpatient COPD population where LV disease was thoroughly excluded, we
observed that only PaO2 was a significant predictor of mPAP. PaO2 at rest and peak exercise
below 9.5 kPa (71 mmHg) and 8.5 kPa (64 mmHg), respectively, indicates the need for further
evaluation of coexisting PH.
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on a bicycle were reasons for exclusion. Prior to inclusionChronic obstructive pulmonary disease (COPD) is a common
cause of pre-capillary pulmonary hypertension (PH).1
However, this complication may be overlooked in COPD
patients, as symptoms are attributed to ventilatory limi-
tation. The PH due to COPD is often mild to moderate,2,3
but is nevertheless associated with increased morbidity
and mortality.4 We have previously reported that PH is
quite frequent in an outpatient COPD cohort5 and recom-
mended to pay attention to this complication. When eval-
uating COPD patients, predictors of PH should be
specifically assessed, and the present study focuses on
variables readily available in a pulmonary outpatient clinic.
In this aspect, hypoxia is important, because of its associ-
ation with the development of PH.6 Vasoconstriction caused
by alveolar hypoxia, as well as remodeling of the small
pulmonary arteries, are important parts of the pathological
process.7e9 Hypoxemia at rest is associated with poorer
prognosis.10 Preceding respiratory failure, many patients
experience hypoxemia during exercise, which may repre-
sent an early sign of compromised pulmonary circulation. In
order to evaluate the relationship between PH and hypox-
emia, we will focus on arterial oxygen tension (PaO2) both
at rest and during exercise.
Smoking is a common risk factor of both COPD and car-
diovascular disease. Prior studies of PH in COPD have re-
ported a high prevalence of left ventricular (LV)
dysfunction, characterized by elevated pulmonary capillary
wedge pressure (PCWP).11e13 This contributes to elevated
mean pulmonary artery pressure (mPAP) of the post-
capillary type. To avoid this, we have recruited stable
COPD patients with a thorough exclusion of LV dysfunction
to focus only on the pre-capillary PH.
The present study has recruited ordinary COPD patients
from a local pulmonary outpatient clinic, whereas prior
invasive studies of PH in COPD often have recruited highly
preselected patients referred to specialized PH-centers or
transplant evaluation.
The aims of this study were thus to (i) evaluate the
relationship between mPAP and PaO2, (ii) identify signifi-
cant predictors of mPAP and PaO2 and (iii) use PaO2 as a
marker of PH.Methods
Study population
During the period 2006e10, consecutive patients with sta-
ble COPD were invited to a cross sectional study at the
Outpatient Department of Pulmonary Medicine at Oslo
University Hospital, Aker.5 Patients aged 40e75 years, with
a smoking history of at least 10 pack-years and a minimum
of eight weeks since last exacerbation, were asked to
participate. The COPD diagnosis was verified by spirometry
performed before and after bronchodilatation according to
the GOLD guidelines.14 Exclusion criteria included all pul-
monary diseases other than COPD or emphysema.
Obstructive sleep apnea syndrome, pulmonary embolism
and severe systemic hypertension, as well as the use ofbeta blockers and anticoagulants or the inability to exercise
all patients were examined by a cardiologist to exclude
coronary or valvular disease, LV dysfunction or arrhythmia.
Electrocardiogram at rest and during exercise was per-
formed for all patients, echocardiography only in those
with heart murmur or untreated mild systemic hyperten-
sion. Fig. 1 is a flow chart describing the inclusion process.
Study protocol
Patients underwent the test program over two days. They
were instructed to take their regular daily medication. All
tests were performed without supplementary oxygen.
Spirometry, body plethysmography and transfer factor of
the lung for carbon monoxide (DLCO) measurement
(Jaeger, MasterScreen PFT, Wurtsburg, Germany) were
performed with the patient sitting upright. DLCO was
measured in patients who had forced vital capacity (FVC)
1.5 L using single breath method.15 Norwegian reference
values for spirometry16 and DLCO17 were used, for static
lung volumes European reference values were applied.18
Arterial blood samples were obtained from a radial ar-
tery cannula inserted under local anesthesia. Blood gases at
rest were first obtained with the patient in supine position
and then sitting upright on the cycle ergometer. During
exercise, blood gases were obtained every fourth minute
and at peak exercise. All sample syringes (Portex, Smiths
Medical, Keene, USA) were kept on ice until the end of
exercise and then analyzed (Cobas b 221, Roche, Indian-
apolis, USA). Exercise test was performed on an electroni-
cally braked cycle ergometer (Ergoline Variobike 550,
Jaeger, Germany). A stepwise incremental protocol was
applied with 4 min of unloaded pedaling, 4 min of 25 W,
followed by an increase of 10 W every second minute until
exhaustion.
Right heart catheterization (RHC) (Mac-Lab, GE Health-
care, Milwaukee, USA) was performed with the patient in
the supine position. A 7F SwaneGanz catheter was inserted
in the medial antecubital or femoral vein and positioned in
the pulmonary artery under guidance of fluoroscopy. Pres-
sure transducers were balanced against the atmospheric
pressure at right atrial level. Pressure measurements were
made during breath-hold at end-expiration. Cardiac output
(CO) was measured by thermodilution technique, averaging
three or five output measurements.5 Pulmonary artery
pressures were measured at rest and PH was defined as
mPAP  25 and PCWP 15 mmHg.19
Doppler echocardiography (Vivid 7, GE Vingmed Ultra-
sound, Horten, Norway) was performed during breath-hold
at end-expiration from left parasternal long- and short-axis
and apical four-chamber view.
The study has been performed according to the Helsinki
Declaration and approved by the Regional Ethical Com-
mittee. Written informed consent was obtained from all
participants.
Statistical analyses
All analyses were performed using IBM SPSS Statistics,
version 19. Continuous variables were reported as mean
Figure 1 Flow chart describing the inclusion process and examination of COPD patients.
Pulmonary artery pressure and PaO2 in COPD 1273(SD). Independent sample t-test was used to compare mean
values for two groups. Paired sample t-test was used to
compare the mean difference in the supine and sitting
position within the same group. One-way ANOVA with
Bonferroni correction was used to compare more than two
groups. A significance level of two-tailed p values <0.05
was used for all analyses.
Normality distribution for the dependent variables in
Table 4 was evaluated by visual inspection and ShapiroeWilk
test. Multiple linear regression analyses were used to
determine independent predictors of mPAP and PaO2. All
significant univariate variables were entered in the full
model. Thereafter, backward stepwise eliminations were
performed for non-significant (p > 0.05) variables.Receiver operating characteristic curve analysis (ROC)
was performed to test the diagnostic accuracy for
discrimination of COPD patients with PH from those without
and to determine optimal cut-off values for PaO2.Results
The demographic characteristics are presented in Table 1,
classified by severity in the GOLD stages.14 No significant
differences were found in gender, age, height or smoking
habits between the different stages. Body mass index (BMI)
was lower in patients with the most severe disease, stage IV,
compared to stages II and III. As expected, variables
1274 I. Skjørten et al.describing pulmonary function were all different between
the GOLD stages.
A gradual increase in mPAP was observed with increasing
COPDseverity (Table1).PHwasobserved in25 subjects (26%),
all but one had mild to moderate disease. Nineteen and five
patients had mPAP in the range 25e29 and 30e39 mmHg,
respectively. The highest mPAP measured was 40 mmHg and
observed inonepatient only.Whenpatientswereclassifiedby
the presence of PH, there were no differences regarding de-
mographic data, but significant differences in pulmonary
function.5 All subjects had PCWP below 15 mmHg, consistent
with the exclusion of patients with LV dysfunction.
Respiratory failure, defined as PaO2 <8 kPa, was
observed in 14 patients and seven of these qualified for long
term oxygen treatment (LTOT). Ambulatory oxygen wasTable 1 Subject characteristics in 95 patients with COPD in GO
GOLD II
n Z 37
GO
n Z
Demographics
Women/men 18/19 13/
Age, yrs 65 (6) 6
Height, cm 169 (9) 17
BMI, kg/m2 26 (4) 2
Pack-years 41 (17) 4
Pulmonary function
FEV1, L 1.81 (0.53) 1.2
FEV1 % predicted 59 (8) 4
FEV1/FVC % 56 (7) 4
DLCOa % predicted 66 (15) 5
RVb % predicted 160 (26) 21
TLCb % predicted 116 (12) 12
RV/TLCb % 52 (7) 6
Hemodynamics
Heart rate, beats/min 74 (11) 7
mPAP, mmHg 18 (4) 2
PCWP, mmHg 9 (4) 1
RAP, mmHg 5 (3)
CI, L/min/m2 2.9 (0.4) 2.
PVR, Wu 1.7 (0.7) 2.
TPR, Wu 3.5 (0.9) 3.
Echocardiography
LV ejection fraction, % 57 (4) 5
LV E/A-ratio 1.10 (0.26) 1.1
LV E/E0-ratio 8.9 (2.2) 9.
LA volume, ml/m2 24 (4) 2
PAAcT, ms 127 (14) 12
TAPSE, cm 2.27 (0.27) 2.0
RV FAC, % 0.40 (0.08) 0.3
RV FS, % 42 (15) 4
Data are presented as mean (SD). FEV1: forced expiratory volume in 1
for carbon monoxide; RV: residual volume; TLC: total lung capacity; m
wedge pressure; CI: cardiac index; PVR: pulmonary vascular resistanc
left ventricular; E: transmitral early diastolic velocity; A: late diastoli
LA: left atrial; PAAcT: pulmonary artery acceleration time; TAPSE: tric
fractional area shortening; FS: fractional shortening.
a DLCO was missing in 10 subjects: three in GOLD stage III and seve
b RV and TLC were missing in three subjects, all in GOLD stage IV. p-v
variable. Significant differences within each variable are indicated asused by four patients. Alfa1-antitrypsin deficiency was
observed in altogether four patients; one in GOLD stages II
and III and two in stage IV. A mean (SD) tobacco consump-
tion of 41 (19) pack-years was reported for the total group.
Active smoking was reported in 32% of the subjects, while
68% were ex-smokers. Systemic hypertension and diabetes
mellitus were present in 35% and 8% of the subjects,
respectively, but did not vary significantly with GOLD stages
or with the presence of PH. Regular use of inhaled medi-
cation was observed in 93% of the study population. Com-
bination therapy with long-acting beta2-stimulators and
inhaled corticosteroids was used by 64%, beta2-stimulators
by 64% and anticholinergic medication by 80%. Theophyllin
was used by 13%. Oral corticosteroid maintenance therapy
was used by 15%, mainly by patients in GOLD stage IV.LD stages IIeIV.
LD III
29
GOLD IV
n Z 29
p-value
ANOVA
16 16/13 0.73 (NS)
3 (8) 62 (6) 0.44 (NS)
0 (10) 168 (10) 0.71 (NS)
6 (5) 22 (6){þ 0.008
3 (23) 38 (17) 0.55 (NS)
7 (0.40){ 0.74 (0.19){þ <0.001
0 (6){ 25 (7){þ <0.001
6 (10){ 39 (10){þ <0.001
2 (14){ 28 (13){þ <0.001
1 (64){ 267 (45){þ <0.001
6 (28) 138 (20){ <0.001
2 (11){ 72 (5){þ <0.001
4 (14) 84 (12){þ 0.002
0 (6) 25 (6){þ <0.001
0 (4) 9 (4) 0.54 (NS)
6 (4) 6 (4) 0.60 (NS)
9 (0.4) 3.0 (0.5) 0.43 (NS)
0 (0.8) 3.3 (1.5){þ <0.001
9 (1.1) 5.1 (1.6){þ <0.001
6 (3) 58 (5)þ 0.032
0 (0.30) 0.96 (0.24) 0.053 (NS)
2 (2.2) 9.5 (2.3) 0.62 (NS)
3 (6) 22 (5) 0.18 (NS)
1 (22) 102 (17){þ <0.001
9 (0.32) 1.95 (0.34){ <0.001
5 (0.09){ 0.36 (0.07) 0.013
1 (13) 35 (11) 0.097 (NS)
s; FVC: forced vital capacity; DLCO: diffusion capacity of the lung
PAP: mean pulmonary artery pressure; PCWP: pulmonary capillary
e; TPR: total pulmonary resistance; RAP: right atrial pressure; LV:
c velocity; E0: septal mitral annular early diastolic tissue velocity;
uspid annulus plane systolic excursion; RV: right ventricular; FAC:
n in stage IV.
alues refer to ANOVA comparing GOLD stages II, III and IV for each
{: different from GOLD stage II; þ: different from GOLD stage III.
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rest and during exercise (Table 2). No significant effect of
body posture on PaO2 could be demonstrated, mean PaO2
(SD) was 9.4 (1.4) in both the supine and sitting positions.
A decline in PaO2 during exercise was observed in 73% of
the subjects, whereas 27% experienced no change or an
increase in PaO2. The mean change in PaO2 from rest to
peak exercise (DPaO2) was most pronounced in GOLD
stages III and IV, and patients with most severe hypoxemia
at rest experienced the largest fall in PaO2 during exercise
(Table 2).
Arterial carbon dioxide tension (PaCO2) increased with
advancing GOLD stages both at rest and during exercise
(Table 2). No difference was found in PaCO2 comparing
supine and sitting positions for the total cohort, mean (SD)
was 5.4 (0.7) kPa in both positions.
Fig. 2 shows the univariate relationships between mPAP
and PaO2 both at rest and at peak exercise. Significant
correlations were observed for both plots. Mean PaO2 at
rest was 8.3 (1.5) kPa in the group with PH, which was
significantly lower than 9.8 (1.2) kPa in the group without
PH (p < 0.001). At peak exercise, mean PaO2 was 7.3 (1.9)
and 9.3 (1.6) kPa in the group with and without PH,
respectively (p < 0.001).
The univariate relations between the independent vari-
ables and mPAP, as well as PaO2 at rest and peak exercise
are shown in Table 3. Significant differences were observed
for FEV1, residual volume (RV)/total lung capacity (TLC)
ratio and heart rate (HR).
Multivariate regression analyses are shown in Table 4 and
were performed with gender, age, height and the signifi-
cant independent variables from Table 3 in the models. The
model for mPAP also included PaO2 at rest and revealed
PaO2 as the only significant predictor, accounting for 35% of
the total variance (Table 4). The models for PaO2 at rest
and PaO2 at peak exercise included mPAP. The adjusted
multivariate models for PaO2 at rest and PaO2 at peak ex-
ercise revealed FEV1 and mPAP as significant predictors,
together accounting for 46 and 56% of the total variance,
respectively (Table 4). No first order interactions were
observed between the significant independent variables in
any of the models.
Fig. 3 shows the relationship between PaO2 at rest and at
peak exercise for subjects with and without pulmonary
hypertension. We have applied different cut-off values ofTable 2 PaO2 and PaCO2 in GOLD stages IIeIV (n Z 95).
GOLD II
n Z 37
PaO2, rest, sitting position, kPa 10.2 (1.0)
PaO2, rest, supine position, kPa 10.0 (1.2)
PaO2, peak exercise, kPa 10.3 (1.2)
DPaO2, kPa 0.1 (1.3)
PaCO2, rest, sitting position, kPa 5.1 (0.4)
PaCO2, rest, supine position, kPa 5.1 (0.5)
PaCO2, peak exercise, kPa 5.1 (0.6)
DPaCO2, kPa 0.0 (0.4)
Data are presented as mean (SD). PaO2: arterial oxygen tension
exercise  rest. {: different from GOLD stage II; þ: different from GOPaO2, in order to obtain optimal detection- and false-
positive rates for prediction of PH. Fig. 4 shows ROC
curves for PaO2 at rest and peak exercise. Area under the
curve is 0.77 (95% CI 0.66, 0.88) and 0.81 (95% CI 0.70, 0.93)
for PaO2 at rest and at peak exercise, respectively. With a
cut-off value of PaO2 at rest 9.5 kPa, the detection rate
was 80%, the false-positive and false-negative rates were 41
and 20%, respectively. With a cut-off value of PaO2 at peak
exercise 8.5 kPa, the detection rate was 88%, the false-
positive and false-negative rates were 31 and 12%,
respectively. By combining the two, a detection rate of 76%
and a false-positive and false-negative rate of 24% were
obtained.Discussion
The present study has shown in an outpatient COPD popu-
lation, where LV disease was thoroughly excluded, that only
PaO2 was a significant predictor of mPAP when adjusted for
demographic data and pulmonary obstructive indices.
When assessing the presence of PH in COPD, the combined
evaluation of PaO2 at rest and at peak exercise proved
useful.
Consistent with numerous previous studies in COPD pa-
tients, we observed a clear inverse relationship between
mPAP and PaO2.
3,12 This is due to hypoxic vasoconstriction
and vascular remodeling of small pulmonary arteries. In our
study, only PaO2 was a significant predictor of mPAP,
whereas in a study of COPD patients with end-stage disease
evaluated for lung transplantation, both PaO2 and PaCO2
were significant predictors.12 This discrepancy may be
explained by the lower PaCO2 with less variance both in the
group with and without PH in our cohort. Indices of airway
obstruction failed to predict mPAP. This is in contrast to a
study of COPD patients with severe emphysema where
FEV1, and not PaO2, was a predictor of mPAP.
11 However,
severely hypoxic patients were excluded from their study
and supplementary oxygen was provided during RHC.
DLCO was missing in 20% of patients with PH, in contrast
to 7% in patients without PH. Although DLCO correlates with
mPAP and PaO2, it introduces a bias in multivariate
regression analyses by excluding many subjects with severe
disease. DLCO was not included in the final model of mul-
tiple regression analyses as this would restrict our analysesGOLD III
n Z 29
GOLD IV
n Z 29
p-value
ANOVA
9.7 (1.1) 8.1 (1.3){þ <0.001
9.7 (1.1) 8.2 (1.2){þ <0.001
8.8 (1.6){ 7.0 (1.2){þ <0.001
1.0 (1.5){ 1.1 (0.7){ <0.001
5.3 (0.6) 5.9 (0.7){þ <0.001
5.4 (0.6) 5.8 (0.7){ <0.001
5.8 (0.8){ 6.5 (0.9){þ <0.001
0.5 (0.5){ 0.6 (0.4){ <0.001
; PaCO2: arterial carbon dioxide tension; D: difference peak
LD stage III.
Figure 2 The relationships between mean pulmonary artery pressure (mPAP) and (a) PaO2 at rest; (b) PaO2 at peak exercise with
the corresponding regression lines. B: GOLD stage II; C: GOLD stage III; :: GOLD stage IV.
1276 I. Skjørten et al.to only 85 patients. However, when we tried to include
DLCO in the regression model in Table 4 anyway, it did not
reach significance in predicting mPAP. The missing DLCO
measurements were related to inability to hold the breath
sufficiently and to low FVC which makes the single breath
method unreliable. Rebreathing technique for DLCO mea-
surement could possibly have overcome this problem.30
Although FEV1 failed to predict mPAP in our study, it was
a significant predictor of PaO2 both at rest and at peak
exercise together with mPAP. In a COPD population from
Norway, heart rate, FEV1 % predicted, fat mass index and
TLC were found to be significant predictors of PaO2 at rest,
accounting for only 19% of the total variance.20 In our
cohort, their model would account for 36% of the total
variance (adjusted R2 Z 0.355). By including mPAP in the
multiple regression analyses, we could demonstrate a sub-
stantial improvement in the explained variance for PaO2 at
rest and observed that heart rate was no longer significant.
By clinical evaluation alone it is difficult to identify
COPD patients prone to develop PH. Our data suggest that
PH should be considered when PaO2 at rest is below 9.5 kPa
in stable COPD patients without LV disease. The cut-offTable 3 Univariate linear regression for mPAP and PaO2 in 95 p
Univariate predictors of mPAP,
mmHg
Univariate
PaO2 rest,
Beta coefficient (95% CI) p Beta coeffi
Gender
Female Reference Reference
Male 0.63 (3.05, 1.79) 0.61 0.54 (0
Age, yrs 0.07 (0.25, 0.12) 0.46 0.01 (0
Height, cm 0.08 (0.21, 0.05) 0.21 0.03 (0.0
BMI, kg/m2 0.15 (0.08, 0.39) 0.20 0.03 (0
FEV1, L 3.84 (5.69, 1.98) <0.001 1.36 (0.9
RV/TLC 23.0 (13.1, 33.0) <0.001 7.1 (9
Heart rate 0.10 (0.03, 0.17) 0.004 0.03 (0
PaO2 rest, kPa 2.43 (3.12, 1.75) <0.001
mPAP, mmHg 0.14 (0
Univariate linear regression analysis. PaO2: arterial oxygen tension; B
residual volume; TLC: total lung capacity; mPAP: mean pulmonary arlevel at rest was higher than we initially expected, as PH
in COPD often is associated with respiratory failure. The
higher PaO2 could be related to our strict exclusion criteria,
as no patients with LV disease, interstitial parenchymal
disease or other diagnoses known to affect gas exchange
were included, but should reflect a COPD population of pre-
capillary PH. Our observed mean PaO2 in subjects with PH
was comparable to previous COPD studies.12,21e24 However,
only two of these studies12,21 have reported mPAP and PaO2
on an individual level. Similar to us, they observed sur-
prisingly high PaO2 in some subjects with PH, suggesting
that there is a large variation in PaO2. Moreover, patients
with PaO2 >8 kPa when sitting upright at rest, may expe-
rience hypoxemia with change of position, activity level or
during sleep. Thus, when we incorporated PaO2 measured
at rest in the supine position in our ROC curve analysis, a
cut-off value of 9.1 kPa achieved the same sensitivity
(80%) as a cut-off value of 9.5 kPa in the sitting position.
However, in outpatient clinics, PaO2 is usually obtained in
the sitting position.
The cut-off level of PaO2 9.5 at rest gave a false-
positive rate as high as 41%. Although PaO2 at peakatients with COPD.
predictors of
kPa
Univariate predictors of PaO2
peak exercise, kPa
cient (95% CI) p Beta coefficient (95% CI) p
Reference
.04, 1.12) 0.066 0.93 (0.17, 1.69) 0.018
.05, 0.04) 0.76 0.01 (0.06, 0.07) 0.87
0, 0.06) 0.049 0.05 (0.01, 0.09) 0.025
.02, 0.09) 0.25 0.07 (0.01, 0.15) 0.07
5, 1.76) <0.001 2.22 (1.76, 2.69) <0.001
.3, 4.8) <0.001 11.2 (13.9, 8.5) <0.001
.05, 0.01) <0.001 0.03 (0.06, 0.01) 0.003
.18, 0.10) <0.001 0.17 (0.23, 0.12) <0.001
MI: body mass index; FEV1: forced expiratory volume in 1 s; RV:
tery pressure.
Table 4 Independent predictors of mPAP and PaO2 in 95 patients with COPD.
Factor Regression
coefficient
Std. error 95% Confidence
interval
p-value Adjusted R2
mPAP, mmHg 0.35
PaO2 rest, kPa 2.45 0.35 3.15, 1.75 <0.001
PaO2 rest, sitting position, kPa 0.46
FEV1, L 1.02 0.23 0.56, 1.48 <0.001
mPAP, mmHg 0.11 0.02 0.15, 0.07 <0.001
PaO2 peak exercise, kPa 0.56
FEV1, L 2.08 0.28 1.53, 2.64 <0.001
mPAP, mmHg 0.09 0.03 0.14, 0.04 <0.001
Multiple linear regression analysis adjusted for gender, age and height. mPAP: mean pulmonary artery pressure; PaO2: arterial oxygen
tension; FEV1: forced expiratory volume in 1 s.
Pulmonary artery pressure and PaO2 in COPD 1277exercise requires more effort to obtain, we observed that it
was better to distinguish between patients with and
without PH (Fig. 4). By adding a cut-off level of PaO2 8.5
at peak exercise the false-positive rate was reduced. When
we applied these cut-off values to our RHC cohort of 95
subjects, 49 subjects had PaO2 9.5 kPa at rest. During the
exercise test, 36 of these developed PaO2 8.5 kPa at peak
exercise, which identified 19 of the 25 subjects with PH. Of
the remaining 17 subjects with PaO2 9.5 at rest and 8.5
at peak exercise, only nine had mPAP 20 mmHg. Alto-
gether eight subjects had mPAP of 21e24 mmHg and may be
at risk of developing PH. A false-positive rate of 24% seems
high, but it includes many patients with borderline pa-
thology. To identify two more subjects with PH, the cut-off
limit for PaO2 at rest would have had to be increased to
10.3 kPa. Although this would have increased the detection
rate, many patients without PH would have been investi-
gated unnecessarily. To assess whether COPD patients have
PH or not, we therefore suggest that patients with PaO2Figure 3 The relationship between PaO2 at rest and PaO2 at
peak exercise with cut-off values of 9.5 and 8.5 kPa, respec-
tively. Black: mPAP  25 mmHg; white: mPAP < 25 mmHg.9.5 kPa at rest should perform an exercise test. If PaO2 at
peak exercise reaches 8.5 kPa or below, further PH inves-
tigation is recommended.
We found normal PCWP in all patients, which is rather
unusual in a COPD cohort, as many patients have cardio-
vascular comorbidity. Reasons for this could be our strict
evaluation of patients prior to inclusion. Echocardiography
performed in all study patients showed a normal left ven-
tricular ejection fraction indicating a preserved systolic
function. Echocardiographic surrogates for LV filling pres-
sures were all within normal limits indicating a normal
diastolic function. We cannot entirely rule out the presence
of diastolic dysfunction, as some patients have measure-
ments equal to the upper limit of normal. Moreover, PCWP
tends to increase with age and a study of patients with
suspected idiopathic pulmonary arterial hypertension found
higher PCWP in patients aged 65 or older compared to the
younger group.25 However, results from the ASPIRE study
have shown no difference in the prevalence of cardiacFigure 4 ROC curves for the prediction of pulmonary hy-
pertension; solid line: PaO2 at peak exercise; dotted line: PaO2
at rest.
1278 I. Skjørten et al.comorbidities comparing groups with normal and high PCWP
in COPD patients with severe PH.26
Our multivariate analyses are based upon variables ob-
tained in pulmonary outpatient clinics. When variables
from echocardiography were entered in the multivariate
regression model presented in Table 4, pulmonary artery
acceleration time (p < 0.001), left ventricular transmitral
early diastolic velocity/septal mitral annular early diastolic
tissue velocity (E/E0) (p Z 0.018) and PaO2 (p Z 0.001)
were significant predictors of mPAP. Although PaO2 is not
the only significant variable in such a model, it still remains
a very strong predictor.
Assessment of the pulmonary circulation should also
include evaluation of cardiac index (CI). No significant dif-
ference in CI was found between the GOLD stages, they were
all within normal range. The higher mPAP in stage IV was not
paralleled by reducedCI. A hyperkinetic circulation, induced
by hypoxemia, may account for this, as patients in GOLD
stage IV demonstrated lower PaO2 and higher heart rate.
Severe PH was observed in only one patient with mPAP of
40 mmHg. This patient had FEV1 of 47% predicted and may
classify as PH out of proportion to pulmonary function. Such
a patient is important to identify and should be referred for
evaluation regarding targeted pulmonary vascular ther-
apy.3,26 The prevalence of severe PH in COPD is still un-
certain, but a reported prevalence of 1%3 fits well with our
observation. Currently, there are no treatment options for
COPD patients with mild to moderate PH except for anti-
obstructive treatment and LTOT. However, identifying
these patients provides substantial prognostic information4
as conventional prognostic models for COPD may be
different for PH in COPD.26
Limitations
Our study population included highly selected COPD pa-
tients, representing only 9% of the total COPD population
registered in our outpatient clinic. Thus, they are not
necessarily representative of the general COPD population
with several comorbidities.27 However, excluding comor-
bidities that affect LV function allowed us to focus on pre-
capillary PH, as significant post-capillary contribution to
elevated mPAP was minimized. Our cohort reflects all
stages of COPD recruited from an ordinary outpatient
clinic, which contrasts many previous studies of COPD pa-
tients with end-stage disease evaluated for transplantation
or volume reduction surgery.11,12
The exercise test with measurement of PaO2 and the
RHC were performed as two separate examinations.
Different body positions may also have influenced the re-
sults;28 the exercise test was performed sitting on a bicy-
cle, whereas RHC was performed in the supine position.
However, no effect of body posture on PaO2 was found in
the total cohort. The mode of exercise might have influ-
enced PaO2, as PaO2 at peak exercise is lower on treadmill
compared to bicycle.29
Conclusion
We have shown, in a COPD population where post-capillary
causes for PH have been systematically excluded, thatmPAP is closely associated with PaO2, leaving indices of
obstruction and hyperinflation of less importance. PaO2
both at rest and peak exercise are closely associated with
airflow limitation and pulmonary artery pressure. Manifes-
tation of PaO2 at rest and at peak exercise below 9.5 and
8.5 kPa, respectively, indicates the need for further di-
agnostics, as dysfunction of the pulmonary circulation is
likely to be present in the majority of these patients.
Further studies should be performed in other COPD cohorts
to test our cut-off values in relation to the presence of PH.
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